Italy Continuous Glucose Monitoring Devices Market Size and Share
Market Overview
| Study Period | 2021 - 2032 |
|---|---|
| Forecast Data Period | 2027 - 2032 |
| Base Year Market Size (2026) | USD 413.27 Million |
| Market Size (2027) | USD 451.66 Million |
| Market Size (2032) | USD 704.23 Million |
| Growth Rate (2027 - 2032) | 9.29 % |
| Market Concentration | Low |
Major Players *Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. | |
Italy Continuous Glucose Monitoring Devices Market Analysis by Mordor Intelligence
The Italy Continuous Glucose Monitoring Devices Market size is projected to expand from USD 413.27 million in 2026 and USD 451.66 million in 2027 to USD 704.23 million by 2032, registering a CAGR of 9.29% between 2027 and 2032.
Within the first year since its inception, the COVID-19 pandemic was responsible for premature deaths, particularly among older individuals. Italy was the first country in Europe affected by COVID-19. Italy was among the countries with the highest mortality. Most people who died of COVID-19 were affected by the co-occurrence of two or more chronic conditions in the same individual. Several studies underlined that diabetes was associated with adverse outcomes in COVID-19 patients. The pandemic boosted opportunities for continuing and expanding innovations in the delivery of diabetes care through virtual consultations between healthcare providers and people with diabetes and the use of diabetes technology.
Continuous glucose monitoring devices estimate blood glucose levels throughout the day and night. These devices help determine blood glucose levels at any time, how blood glucose level changes over a few hours or days, and spot trends. Monitoring blood glucose levels in real-time can help the patient or caregivers make more informed decisions about food, physical activities, and medicines. Keeping blood glucose levels in the target range can help prevent other health problems caused by diabetes, including stroke, kidney disease, nerve damage, hearing loss, hypertension, eye complications, foot complications, skin complications, etc.
Continuous Glucose monitoring is an important tool for insulin-treated people with diabetes, measuring interstitial glucose levels and providing information about glucose trends and rate of change. Various studies demonstrate that people with diabetes, both type 1 and type 2, using CGM systems experience fewer hyperglycemic and hypoglycemic episodes and a significant decrease in glycated hemoglobin (HbA1C) levels. Italian guidelines highlight the importance of selecting and educating patients and caregivers about the use of CGM. The guidelines identify poor glucose control and hypoglycemia as the main indications for CGM use, especially in case of problematic hypoglycemia.
Therefore, owing to the aforementioned factors, the studied market is anticipated to witness growth over the analysis period.
Note: Market numbers in this report are based on Mordor Intelligence's proprietary estimation framework, which combines nine months of actuals with Q4 projections for base year 2026.
Italy Continuous Glucose Monitoring Devices Market Trends and Insights
Rising Diabetes Prevalence in Italy
The diabetes population in Italy is expected to grow by about 0.57% over the forecast period.
According to the International Diabetes Federation's latest reports, the prevalence of diabetes in adults in Italy was approximately 9.9%. The Italian health system is highly decentralized, with most administrative and organizational powers held by the regions. The National Diabetes Plan defines priorities and provides guidelines to improve the quality of diabetes care with a patient-centered focus. Regional and local authorities are responsible for its implementation, which varies among the 20 regions. Government policies play a critical role in improving the quality and safety of healthcare in a country at almost all levels of authority - state and local. Policy, systems, and environmental changes are essential to a long-term plan to prevent chronic diseases like diabetes.
The Italian National Healthcare Service (NHS) ensures universal coverage for all citizens. People living with diabetes have access, with no out-of-pocket expenditure, to all the medicines, devices, and medical services they need. Overall, Italy has a well-developed system of diabetes care, with numerous diabetes centers throughout the country and treatment free at the point of delivery.
Therefore, the studied market is anticipated to witness growth over the analysis period due to rising prevalence and the aforementioned factors.
The Sensors Segment holds the highest market share in the current year
The sensors segment holds the highest market share in the current year in the market studied.
A CGM consists of three parts: a sensor, a receiver, and a transmitter. Sensors are basically of two types; a sensor that can be inserted under the skin, with a sticky patch that helps it stay, is called a disposable sensor. Another type of CGM sensor is called an implantable sensor, which may be placed inside the body. CGM sensors estimate the glucose level in the fluid between the cells, which is similar to the glucose level in the blood. Sensors must be replaced at specific times, such as every few weeks, depending on the type.
Technological advances in sensors are likely to boost the segment growth. For instance, future CGM devices may use nanoparticle sensors that may demonstrate exceptional glucose response in the physiological range and are promising for real-time glucose tracking. Technological development is gaining momentum in the market. Over the years, several technological innovations have been developed that have led to the creation of new types of devices that are much less cumbersome and more comfortable for patients compared to traditional ones. Such advantages have helped the rise in the adoption of these products in the Italian market.
Furthermore, Italian law regulates the clinical care of people with diabetes and creates a framework involving medical organizations, prevention programs, personnel training, and legal protection. The National Health Program is structured in essential levels of assistance that can be defined differently in the various regions. The National Health Program is structured in LEAs (essential levels of assistance). LEAs define all the medical assistance modalities offered by the INHS to citizens, with or without partial contributions, based on a patient's income. Such reimbursement policies and the aforementioned factors are expected to drive the market over the forecast period.
Competitive Landscape
The Italian continuous glucose monitoring devices market is consolidated, with few significant players. There have been constant innovations driven by manufacturers such as Abbott, Dexcom, Medtronic, etc., while also adhering to organic growth strategies, which is evident from the R&D spending of these companies.
Italy Continuous Glucose Monitoring Devices Industry Leaders
-
Abbott
-
Medtronic
-
Dexcom
-
Ascensia
-
GlySens
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- November 2023: Chinese company Sibionics obtained a CE Mark for its GS1 continuous glucose monitoring system (CGM), a wearable device that uses an under-the-skin sensor to measure glucose levels in real-time, transmitting the information to a linked handset or mobile phone. The GS1 CGM offers users 14 days of continuous glucose monitoring without the need for frequent calibration. It allows users to transmit glucose data to monitoring devices or mobile apps and generate professional reports.
- September 2023: Medtronic received CE (Conformité Européenne) Mark approval for its new all-in-one, disposable Simplera continuous glucose monitor (CGM) featuring a simple, two-step insertion process. The company's newest no-fingerstick sensor does not require overtape. It is seamlessly integrated with the InPen smart insulin pen, which provides real-time, personalized dosing guidance to help simplify diabetes management.
Italy Continuous Glucose Monitoring Devices Market Report Scope
Continuous glucose monitoring devices are used to diagnose both hyperglycemic and hypoglycemic conditions in diabetic patients throughout the day. The Italian continuous glucose monitoring device market is segmented into components (sensors and durables).
The report offers the value (in USD) and volume (in units) for the above segments.
| Sensors |
| Durables |
| Component | Sensors |
| Durables |
Key Questions Answered in the Report
How big is the Italy Continuous Glucose Monitoring Devices Market?
The Italy Continuous Glucose Monitoring Devices Market size is expected to reach USD 451.66 million in 2027 and grow at a CAGR of 9.29% to reach USD 704.23 million by 2032.
What is the current Italy Continuous Glucose Monitoring Devices Market size?
In 2026, the Italy Continuous Glucose Monitoring Devices Market size is expected to reach USD 413.27 million.
Who are the key players in Italy Continuous Glucose Monitoring Devices Market?
Abbott, Medtronic, Dexcom, Ascensia and GlySens are the major companies operating in the Italy Continuous Glucose Monitoring Devices Market.
What years does this Italy Continuous Glucose Monitoring Devices Market cover, and what was the market size in 2025?
In 2025, the Italy Continuous Glucose Monitoring Devices Market size was estimated at USD 378.14 million. The report covers the Italy Continuous Glucose Monitoring Devices Market historical market size for years: 2021, 2022, 2023, 2024, and 2025. The report also forecasts the Italy Continuous Glucose Monitoring Devices Market size for years: 2027, 2028, 2029, 2030, 2031, and 2032.